Here, we first demonstrate in the LPS-ALI model that both the granules (QFDYGs) and the decoction (QFDYDs) markedly lower lung-injury scores, curb neutrophil infiltration, suppress TNF-α/IL-6/IL-1β, and restore SOD and GSH, proving that core efficacy is independent of dosage form and readily translatable to the clinic. Here, IL1B is linked to acute respiratory distress syndrome.